Table 3.
Cost-Effectiveness Analysis: Matched Analytic Population
| Δ CABG PCI |
Life Years or QALY Gained with CABG |
ICER | % CABG Dominated |
% CABG Dominant |
% <$30,000 /LYG |
% <$50,000 /LYG |
% <$100,000 /LYG |
|
|---|---|---|---|---|---|---|---|---|
| Life years from 2004 through 2008 | $8,079 | 0.2674 | $30,217 | 0 | 0 | 45.0 | 100.0 | 100.0 |
| Lifetime (3% discount) | $12,157 | 0.3172 | $38,330 | 0 | 0 | 0 | 100.0 | 100.0 |
| Quality-adjusted lifetime (3% discount) | $12,157 | 0.3947 | $30,803 | 0 | 0 | 21.0 | 100.0 | 100.0 |